Announcements
- Addex to Present at the Swiss Biotech Day 2024
- Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
- Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
- Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
- Addex to Present at the Bio-Europe Spring 2024 Conference
- Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
- Addex to Present at the Swiss Equities Baader Conference
- Addex to Present at Biotech Showcase™ 2024
- Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
- Addex Creates Treasury Shares
More ▼
Key statistics
On Friday, Addex Therapeutics Ltd (0QNV:LSE) closed at 0.1046, 88.81% above the 52 week low of 0.0554 set on Jan 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 0.1046 |
Average volume | 96.00k |
---|---|
Shares outstanding | 184.35m |
Free float | 153.41m |
P/E (TTM) | -- |
Market cap | 21.29m CHF |
EPS (TTM) | -0.1433 CHF |
Data delayed at least 20 minutes, as of Apr 26 2024 16:56 BST.
More ▼